image
Healthcare - Medical - Devices - NASDAQ - US
$ 6.34
-1.71 %
$ 250 M
Market Cap
-4.4
P/E
1. INTRINSIC VALUE

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves.[ Read More ]

The intrinsic value of one LUNG stock under the base case scenario is HIDDEN Compared to the current market price of 6.34 USD, Pulmonx Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LUNG

image
FINANCIALS
68.7 M REVENUE
27.98%
-61.9 M OPERATING INCOME
-5.62%
-60.8 M NET INCOME
-3.26%
-37.6 M OPERATING CASH FLOW
16.58%
-2.01 M INVESTING CASH FLOW
52.50%
21.4 M FINANCING CASH FLOW
765.70%
20.4 M REVENUE
-1.91%
-14.1 M OPERATING INCOME
-1.61%
-14.1 M NET INCOME
7.71%
-7.24 M OPERATING CASH FLOW
-25.51%
6.75 M INVESTING CASH FLOW
908.50%
459 K FINANCING CASH FLOW
2186.36%
Balance Sheet Decomposition Pulmonx Corporation
image
Current Assets 150 M
Cash & Short-Term Investments 117 M
Receivables 12.1 M
Other Current Assets 21.2 M
Non-Current Assets 27.4 M
Long-Term Investments 14.4 M
PP&E 7.43 M
Other Non-Current Assets 5.54 M
Current Liabilities 23.2 M
Accounts Payable 1.5 M
Short-Term Debt 8.3 M
Other Current Liabilities 13.4 M
Non-Current Liabilities 36.3 M
Long-Term Debt 36.2 M
Other Non-Current Liabilities 114 K
EFFICIENCY
Earnings Waterfall Pulmonx Corporation
image
Revenue 68.7 M
Cost Of Revenue 17.9 M
Gross Profit 50.8 M
Operating Expenses 113 M
Operating Income -61.9 M
Other Expenses -1.09 M
Net Income -60.8 M
RATIOS
73.90% GROSS MARGIN
73.90%
-90.19% OPERATING MARGIN
-90.19%
-88.60% NET MARGIN
-88.60%
-51.42% ROE
-51.42%
-34.22% ROA
-34.22%
-39.41% ROIC
-39.41%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pulmonx Corporation
image
Net Income -60.8 M
Depreciation & Amortization 1.55 M
Capital Expenditures -807 K
Stock-Based Compensation 22.1 M
Change in Working Capital -2.56 M
Others 2.12 M
Free Cash Flow -38.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pulmonx Corporation
image
Wall Street analysts predict an average 1-year price target for LUNG of $12.7 , with forecasts ranging from a low of $10 to a high of $16 .
LUNG Lowest Price Target Wall Street Target
10 USD 57.73%
LUNG Average Price Target Wall Street Target
12.7 USD 99.79%
LUNG Highest Price Target Wall Street Target
16 USD 152.37%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Pulmonx Corporation
image
Sold
0-3 MONTHS
361 K USD 3
3-6 MONTHS
85.7 K USD 2
6-9 MONTHS
469 K USD 4
9-12 MONTHS
443 K USD 4
Bought
97.4 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Oct 17, 2024
Sell 130 K USD
French Glendon E. III
Director
- 20000
6.52 USD
2 months ago
Sep 12, 2024
Sell 162 K USD
French Glendon E. III
Director
- 20000
8.09 USD
2 months ago
Sep 03, 2024
Sell 2.75 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 410
6.71 USD
2 months ago
Sep 03, 2024
Sell 4.84 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 724
6.69 USD
2 months ago
Sep 03, 2024
Sell 12.3 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1842
6.69 USD
2 months ago
Sep 03, 2024
Sell 10.8 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1610
6.71 USD
2 months ago
Sep 03, 2024
Sell 2.88 K USD
Lehman David Aaron
GENERAL COUNSEL
- 429
6.71 USD
2 months ago
Sep 03, 2024
Sell 5.07 K USD
Lehman David Aaron
GENERAL COUNSEL
- 758
6.69 USD
2 months ago
Sep 03, 2024
Sell 19.3 K USD
Lehman David Aaron
GENERAL COUNSEL
- 2890
6.69 USD
2 months ago
Sep 03, 2024
Sell 11.3 K USD
Lehman David Aaron
GENERAL COUNSEL
- 1688
6.69 USD
2 months ago
Aug 20, 2024
Bought 97.4 K USD
Williamson Steven S.
PRESIDENT AND CEO
+ 14245
6.84 USD
4 months ago
Jun 24, 2024
Sell 7.29 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1184
6.16 USD
5 months ago
Jun 03, 2024
Sell 2.85 K USD
Lehman David Aaron
GENERAL COUNSEL
- 409
6.97 USD
5 months ago
Jun 03, 2024
Sell 5.01 K USD
Lehman David Aaron
GENERAL COUNSEL
- 719
6.97 USD
5 months ago
Jun 03, 2024
Sell 19.1 K USD
Lehman David Aaron
GENERAL COUNSEL
- 2744
6.97 USD
5 months ago
Jun 03, 2024
Sell 11.2 K USD
Lehman David Aaron
GENERAL COUNSEL
- 1603
6.97 USD
5 months ago
Jun 03, 2024
Sell 2.68 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 385
6.97 USD
5 months ago
Jun 03, 2024
Sell 4.73 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 678
6.97 USD
5 months ago
Jun 03, 2024
Sell 12 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1724
6.97 USD
5 months ago
Jun 03, 2024
Sell 10.5 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1510
6.97 USD
5 months ago
May 22, 2024
Sell 10.3 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1184
8.71 USD
6 months ago
Apr 22, 2024
Sell 8.87 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1184
7.49 USD
7 months ago
Mar 22, 2024
Sell 11.1 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1184
9.36 USD
8 months ago
Mar 01, 2024
Sell 3.88 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 428
9.06 USD
8 months ago
Mar 01, 2024
Sell 6.82 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 753
9.06 USD
8 months ago
Mar 01, 2024
Sell 17.4 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1916
9.06 USD
8 months ago
Mar 01, 2024
Sell 1.4 K USD
McKune John
INTERIM CFO
- 155
9.06 USD
8 months ago
Mar 01, 2024
Sell 2.3 K USD
McKune John
INTERIM CFO
- 254
9.06 USD
8 months ago
Mar 01, 2024
Sell 6.06 K USD
McKune John
INTERIM CFO
- 669
9.06 USD
8 months ago
Mar 01, 2024
Sell 4.16 K USD
Lehman David Aaron
GENERAL COUNSEL
- 459
9.06 USD
8 months ago
Mar 01, 2024
Sell 7.33 K USD
Lehman David Aaron
GENERAL COUNSEL
- 809
9.06 USD
8 months ago
Mar 01, 2024
Sell 27.9 K USD
Lehman David Aaron
GENERAL COUNSEL
- 3083
9.06 USD
8 months ago
Mar 01, 2024
Sell 10.8 K USD
French Glendon E. III
PRESIDENT AND CEO
- 1189
9.06 USD
8 months ago
Mar 01, 2024
Sell 16.5 K USD
French Glendon E. III
PRESIDENT AND CEO
- 1818
9.06 USD
8 months ago
Mar 01, 2024
Sell 35.8 K USD
French Glendon E. III
PRESIDENT AND CEO
- 3947
9.06 USD
8 months ago
Feb 22, 2024
Sell 16.8 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1184
14.2 USD
9 months ago
Feb 15, 2024
Sell 292 K USD
French Glendon E. III
PRESIDENT AND CEO
- 20000
14.6 USD
9 months ago
Jan 22, 2024
Sell 15.5 K USD
Rose Geoffrey Beran
CHIEF COMMERCIAL OFFICER
- 1184
13.13 USD
9 months ago
Jan 18, 2024
Sell 128 K USD
French Glendon E. III
PRESIDENT AND CEO
- 10000
12.77 USD
10 months ago
Dec 22, 2023
Sell 15.1 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 1184
12.75 USD
10 months ago
Dec 21, 2023
Sell 124 K USD
French Glendon E. III
President and CEO
- 10000
12.42 USD
11 months ago
Dec 01, 2023
Sell 4.09 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 396
10.34 USD
11 months ago
Dec 01, 2023
Sell 7.22 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 698
10.34 USD
11 months ago
Dec 01, 2023
Sell 18.3 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 1774
10.34 USD
11 months ago
Dec 01, 2023
Sell 1.39 K USD
McKune John
Interim CFO
- 135
10.33 USD
11 months ago
Dec 01, 2023
Sell 2.3 K USD
McKune John
Interim CFO
- 222
10.34 USD
11 months ago
Dec 01, 2023
Sell 6.05 K USD
McKune John
Interim CFO
- 585
10.34 USD
11 months ago
Dec 01, 2023
Sell 4.15 K USD
Lehman David Aaron
General Counsel
- 402
10.33 USD
11 months ago
Dec 01, 2023
Sell 7.31 K USD
Lehman David Aaron
General Counsel
- 707
10.34 USD
11 months ago
Dec 01, 2023
Sell 27.9 K USD
Lehman David Aaron
General Counsel
- 2700
10.34 USD
11 months ago
Dec 01, 2023
Sell 10.8 K USD
French Glendon E. III
President and CEO
- 1040
10.34 USD
11 months ago
Dec 01, 2023
Sell 16.5 K USD
French Glendon E. III
President and CEO
- 1591
10.34 USD
11 months ago
Dec 01, 2023
Sell 41.8 K USD
French Glendon E. III
President and CEO
- 4045
10.34 USD
11 months ago
Nov 22, 2023
Sell 12.6 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 1184
10.6 USD
1 year ago
Oct 23, 2023
Sell 9.89 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 1184
8.35 USD
1 year ago
Sep 22, 2023
Sell 12.4 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 1184
10.51 USD
1 year ago
Sep 01, 2023
Sell 3.98 K USD
Sung Derrick
Chief Financial Officer
- 398
10.01 USD
1 year ago
Sep 01, 2023
Sell 7.02 K USD
Sung Derrick
Chief Financial Officer
- 701
10.01 USD
1 year ago
Sep 01, 2023
Sell 31.2 K USD
Sung Derrick
Chief Financial Officer
- 3120
10 USD
1 year ago
Sep 01, 2023
Sell 3.93 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 393
10.01 USD
1 year ago
Sep 01, 2023
Sell 6.92 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 691
10.01 USD
1 year ago
Sep 01, 2023
Sell 17.6 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 1759
10.01 USD
1 year ago
Sep 01, 2023
Sell 3.98 K USD
Lehman David Aaron
General Counsel
- 398
10.01 USD
1 year ago
Sep 01, 2023
Sell 7.02 K USD
Lehman David Aaron
General Counsel
- 701
10.01 USD
1 year ago
Sep 01, 2023
Sell 26.8 K USD
Lehman David Aaron
General Counsel
- 2673
10.01 USD
1 year ago
Sep 01, 2023
Sell 10.3 K USD
French Glendon E. III
President and CEO
- 1031
10.01 USD
1 year ago
Sep 01, 2023
Sell 15.8 K USD
French Glendon E. III
President and CEO
- 1575
10.01 USD
1 year ago
Sep 01, 2023
Sell 39.2 K USD
French Glendon E. III
President and CEO
- 3921
10.01 USD
1 year ago
Aug 23, 2023
Sell 12.5 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 1184
10.54 USD
1 year ago
Jul 20, 2023
Sell 190 K USD
French Glendon E. III
President and CEO
- 15000
12.68 USD
1 year ago
Jun 15, 2023
Sell 127 K USD
French Glendon E. III
President and CEO
- 10000
12.68 USD
1 year ago
Jun 01, 2023
Sell 4.58 K USD
Sung Derrick
Chief Financial Officer
- 399
11.48 USD
1 year ago
Jun 01, 2023
Sell 8.05 K USD
Sung Derrick
Chief Financial Officer
- 701
11.49 USD
1 year ago
Jun 01, 2023
Sell 35.9 K USD
Sung Derrick
Chief Financial Officer
- 3122
11.49 USD
1 year ago
Jun 01, 2023
Sell 4.51 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 393
11.48 USD
1 year ago
Jun 01, 2023
Sell 7.94 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 692
11.48 USD
1 year ago
Jun 01, 2023
Sell 20.2 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 1760
11.48 USD
1 year ago
Jun 01, 2023
Sell 4.58 K USD
Lehman David Aaron
General Counsel
- 399
11.48 USD
1 year ago
Jun 01, 2023
Sell 8.05 K USD
Lehman David Aaron
General Counsel
- 701
11.48 USD
1 year ago
Jun 01, 2023
Sell 30.7 K USD
Lehman David Aaron
General Counsel
- 2676
11.48 USD
1 year ago
Jun 01, 2023
Sell 11.9 K USD
French Glendon E. III
President and CEO
- 1032
11.49 USD
1 year ago
Jun 01, 2023
Sell 18.1 K USD
French Glendon E. III
President and CEO
- 1577
11.48 USD
1 year ago
Jun 01, 2023
Sell 45 K USD
French Glendon E. III
President and CEO
- 3924
11.48 USD
1 year ago
Mar 01, 2023
Sell 5.05 K USD
Sung Derrick
Chief Financial Officer
- 458
11.03 USD
1 year ago
Mar 01, 2023
Sell 8.89 K USD
Sung Derrick
Chief Financial Officer
- 806
11.03 USD
1 year ago
Mar 01, 2023
Sell 4.82 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 437
11.03 USD
1 year ago
Mar 01, 2023
Sell 8.48 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 769
11.03 USD
1 year ago
Mar 01, 2023
Sell 5.05 K USD
Lehman David Aaron
General Counsel
- 458
11.03 USD
1 year ago
Mar 01, 2023
Sell 8.89 K USD
Lehman David Aaron
General Counsel
- 806
11.03 USD
1 year ago
Mar 01, 2023
Sell 13.1 K USD
French Glendon E. III
President and CEO
- 1184
11.03 USD
1 year ago
Mar 01, 2023
Sell 18.9 K USD
French Glendon E. III
President and CEO
- 1711
11.03 USD
1 year ago
Dec 01, 2022
Sell 8.52 K USD
French Glendon E. III
President and CEO
- 1436
5.93 USD
1 year ago
Dec 01, 2022
Sell 13 K USD
French Glendon E. III
President and CEO
- 2195
5.93 USD
1 year ago
Dec 01, 2022
Sell 2.29 K USD
Lehman David Aaron
General Counsel
- 387
5.93 USD
1 year ago
Dec 01, 2022
Sell 4.04 K USD
Lehman David Aaron
General Counsel
- 682
5.93 USD
1 year ago
Dec 01, 2022
Sell 2.27 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 382
5.93 USD
1 year ago
Dec 01, 2022
Sell 3.99 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 673
5.93 USD
1 year ago
Dec 01, 2022
Sell 2.29 K USD
Sung Derrick
Chief Financial Officer
- 387
5.93 USD
1 year ago
Dec 01, 2022
Sell 4.04 K USD
Sung Derrick
Chief Financial Officer
- 682
5.93 USD
1 year ago
Nov 29, 2022
Bought 9.37 K USD
Lynch Alissa Hsu
Director
+ 1700
5.51 USD
2 years ago
Nov 08, 2022
Bought 529 USD
Ferrari Richard
Director
+ 100
5.29 USD
2 years ago
Nov 08, 2022
Bought 28.3 K USD
Ferrari Richard
Director
+ 5338
5.31 USD
2 years ago
Sep 01, 2022
Sell 7.01 K USD
Sung Derrick
Chief Financial Officer
- 392
17.87 USD
2 years ago
Sep 01, 2022
Sell 6.65 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 372
17.87 USD
2 years ago
Sep 01, 2022
Sell 7.01 K USD
Lehman David Aaron
General Counsel
- 392
17.89 USD
2 years ago
Sep 01, 2022
Sell 12.3 K USD
Lehman David Aaron
General Counsel
- 690
17.88 USD
2 years ago
Sep 01, 2022
Sell 18.1 K USD
French Glendon E. III
President and CEO
- 1014
17.87 USD
2 years ago
Aug 18, 2022
Sell 1.03 M USD
French Glendon E. III
President and CEO
- 50000
20.59 USD
2 years ago
Jun 01, 2022
Sell 6.61 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 366
18.05 USD
2 years ago
Jun 01, 2022
Sell 6.97 K USD
Sung Derrick
Chief Financial Officer
- 386
18.05 USD
2 years ago
Jun 01, 2022
Sell 27.5 K USD
French Glendon E. III
President and CEO
- 1525
18.05 USD
2 years ago
Jun 01, 2022
Sell 6.97 K USD
Lehman David Aaron
General Counsel
- 386
18.05 USD
2 years ago
Jun 01, 2022
Sell 12.3 K USD
Lehman David Aaron
General Counsel
- 679
18.05 USD
2 years ago
Mar 01, 2022
Sell 11.9 K USD
Sung Derrick
Chief Financial Officer
- 458
25.91 USD
2 years ago
Mar 01, 2022
Sell 11 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 426
25.91 USD
2 years ago
Mar 01, 2022
Sell 11.9 K USD
Lehman David Aaron
General Counsel
- 458
25.91 USD
2 years ago
Mar 01, 2022
Sell 29.3 K USD
French Glendon E. III
President and CEO
- 1132
25.91 USD
2 years ago
Feb 17, 2022
Sell 340 K USD
French Glendon E. III
President and CEO
- 12500
27.22 USD
2 years ago
Feb 18, 2022
Sell 230 K USD
French Glendon E. III
President and CEO
- 8561
26.81 USD
2 years ago
Feb 18, 2022
Sell 107 K USD
French Glendon E. III
President and CEO
- 3939
27.13 USD
2 years ago
Jan 20, 2022
Sell 325 K USD
French Glendon E. III
President and CEO
- 12500
25.98 USD
2 years ago
Jan 21, 2022
Sell 293 K USD
French Glendon E. III
President and CEO
- 12113
24.22 USD
2 years ago
Jan 21, 2022
Sell 4.62 K USD
French Glendon E. III
President and CEO
- 187
24.72 USD
2 years ago
Jan 21, 2022
Sell 4.95 K USD
French Glendon E. III
President and CEO
- 200
24.73 USD
2 years ago
Dec 16, 2021
Sell 566 K USD
French Glendon E. III
President and CEO
- 18402
30.74 USD
2 years ago
Dec 16, 2021
Sell 211 K USD
French Glendon E. III
President and CEO
- 6598
31.91 USD
2 years ago
Dec 15, 2021
Sell 661 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 21640
30.53 USD
2 years ago
Dec 15, 2021
Sell 11.3 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 360
31.48 USD
2 years ago
Dec 14, 2021
Sell 98.7 K USD
Sung Derrick
Chief Financial Officer
- 3000
32.89 USD
2 years ago
Dec 15, 2021
Sell 90.8 K USD
Sung Derrick
Chief Financial Officer
- 2976
30.52 USD
2 years ago
Dec 15, 2021
Sell 758 USD
Sung Derrick
Chief Financial Officer
- 24
31.58 USD
2 years ago
Dec 01, 2021
Sell 46.5 K USD
French Glendon E. III
President and CEO
- 1421
32.73 USD
3 years ago
May 20, 2021
Sell 207 K USD
French Glendon E. III
President and CEO
- 5059
41.01 USD
3 years ago
May 20, 2021
Sell 841 K USD
French Glendon E. III
President and CEO
- 19941
42.19 USD
3 years ago
Apr 15, 2021
Sell 872 K USD
French Glendon E. III
President and CEO
- 19989
43.64 USD
3 years ago
Apr 15, 2021
Sell 222 K USD
French Glendon E. III
President and CEO
- 5011
44.21 USD
2 years ago
Dec 01, 2021
Sell 12.5 K USD
Lehman David Aaron
General Counsel
- 383
32.73 USD
2 years ago
Dec 01, 2021
Sell 11.6 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 355
32.73 USD
2 years ago
Dec 01, 2021
Sell 12.5 K USD
Sung Derrick
Chief Financial Officer
- 383
32.73 USD
3 years ago
Nov 18, 2021
Sell 410 K USD
French Glendon E. III
President and CEO
- 11591
35.4 USD
3 years ago
Nov 18, 2021
Sell 482 K USD
French Glendon E. III
President and CEO
- 13209
36.47 USD
3 years ago
Nov 18, 2021
Sell 3.71 K USD
French Glendon E. III
President and CEO
- 100
37.08 USD
3 years ago
Nov 18, 2021
Sell 3.71 K USD
French Glendon E. III
President and CEO
- 100
37.09 USD
3 years ago
Nov 15, 2021
Sell 280 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 7000
39.94 USD
3 years ago
Oct 21, 2021
Sell 650 K USD
French Glendon E. III
President and CEO
- 16403
39.62 USD
3 years ago
Oct 21, 2021
Sell 344 K USD
French Glendon E. III
President and CEO
- 8597
39.99 USD
3 years ago
Oct 15, 2021
Sell 276 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 7000
39.44 USD
3 years ago
Sep 20, 2021
Sell 108 K USD
Sung Derrick
Chief Financial Officer
- 2885
37.33 USD
3 years ago
Sep 20, 2021
Sell 4.37 K USD
Sung Derrick
Chief Financial Officer
- 115
37.96 USD
3 years ago
Sep 21, 2021
Sell 112 K USD
Sung Derrick
Chief Financial Officer
- 3000
37.5 USD
3 years ago
Sep 16, 2021
Sell 972 K USD
French Glendon E. III
President and CEO
- 25000
38.86 USD
3 years ago
Sep 20, 2021
Sell 816 K USD
French Glendon E. III
President and CEO
- 21871
37.31 USD
3 years ago
Sep 20, 2021
Sell 64.6 K USD
French Glendon E. III
President and CEO
- 1700
38.01 USD
3 years ago
Sep 15, 2021
Sell 267 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 7000
38.12 USD
3 years ago
Sep 01, 2021
Sell 15.4 K USD
Sung Derrick
Chief Financial Officer
- 383
40.09 USD
3 years ago
Sep 01, 2021
Sell 14.2 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 355
40.09 USD
3 years ago
Sep 01, 2021
Sell 15.4 K USD
Lehman David Aaron
General Counsel
- 383
40.09 USD
3 years ago
Sep 01, 2021
Sell 57 K USD
French Glendon E. III
President and CEO
- 1421
40.09 USD
3 years ago
Aug 19, 2021
Sell 916 K USD
French Glendon E. III
President and CEO
- 25000
36.63 USD
3 years ago
Aug 19, 2021
Sell 36.6 K USD
French Glendon E. III
President and CEO
- 1000
36.59 USD
3 years ago
Aug 16, 2021
Sell 257 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 7000
36.71 USD
3 years ago
Jul 15, 2021
Sell 28.5 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 758
37.57 USD
3 years ago
Jul 15, 2021
Sell 239 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 6142
38.86 USD
3 years ago
Jul 15, 2021
Sell 3.92 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 100
39.24 USD
3 years ago
Jul 15, 2021
Sell 50.3 K USD
French Glendon E. III
President and CEO
- 1337
37.61 USD
3 years ago
Jul 15, 2021
Sell 434 K USD
French Glendon E. III
President and CEO
- 11163
38.86 USD
3 years ago
Jul 15, 2021
Sell 484 K USD
French Glendon E. III
President and CEO
- 12500
38.73 USD
3 years ago
Jul 15, 2021
Sell 3.49 K USD
French Glendon E. III
President and CEO
- 93
37.53 USD
3 years ago
Jul 15, 2021
Sell 3.82 K USD
French Glendon E. III
President and CEO
- 100
38.2 USD
3 years ago
Jul 15, 2021
Sell 31.4 K USD
French Glendon E. III
President and CEO
- 807
38.9 USD
3 years ago
Jul 13, 2021
Sell 93.6 M USD
BOSTON SCIENTIFIC CORP
10 percent owner
- 2500000
37.45 USD
3 years ago
Jul 12, 2021
Bought 100 K USD
Florin Daniel P
Director
+ 2500
40 USD
3 years ago
Jun 25, 2021
Bought 98 K USD
Florin Daniel P
Director
+ 2222
44.12 USD
3 years ago
Jun 17, 2021
Sell 860 K USD
French Glendon E. III
President and CEO
- 20071
42.83 USD
3 years ago
Jun 17, 2021
Sell 214 K USD
French Glendon E. III
President and CEO
- 4929
43.47 USD
3 years ago
Jun 17, 2021
Sell 42.7 K USD
French Glendon E. III
President and CEO
- 1000
42.68 USD
3 years ago
May 24, 2021
Sell 178 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 4363
40.81 USD
3 years ago
May 24, 2021
Sell 996 USD
Rose Geoffrey Beran
Chief Commercial Officer
- 24
41.49 USD
3 years ago
May 24, 2021
Sell 415 USD
Rose Geoffrey Beran
Chief Commercial Officer
- 10
41.52 USD
3 years ago
May 24, 2021
Sell 16.6 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 400
41.55 USD
3 years ago
May 20, 2021
Sell 207 K USD
French Glendon E. III
President and CEO
- 5059
41.01 USD
3 years ago
May 20, 2021
Sell 841 K USD
French Glendon E. III
President and CEO
- 19941
42.19 USD
3 years ago
May 20, 2021
Sell 40.8 K USD
French Glendon E. III
President and CEO
- 1000
40.75 USD
3 years ago
May 10, 2021
Sell 153 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 3778
40.47 USD
3 years ago
May 10, 2021
Sell 37.3 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 900
41.47 USD
3 years ago
May 10, 2021
Sell 4.99 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 118
42.25 USD
3 years ago
May 10, 2021
Sell 42.5 USD
Rose Geoffrey Beran
Chief Commercial Officer
- 1
42.51 USD
3 years ago
Apr 19, 2021
Sell 207 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 4797
43.24 USD
3 years ago
Apr 15, 2021
Sell 872 K USD
French Glendon E. III
President and CEO
- 19989
43.64 USD
3 years ago
Apr 15, 2021
Sell 222 K USD
French Glendon E. III
President and CEO
- 5011
44.21 USD
3 years ago
Apr 15, 2021
Sell 43.7 K USD
French Glendon E. III
President and CEO
- 1000
43.7 USD
3 years ago
Apr 06, 2021
Sell 28.3 M USD
BOSTON SCIENTIFIC CORP
10 percent owner
- 650000
43.6 USD
3 years ago
Apr 05, 2021
Sell 213 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 4478
47.59 USD
3 years ago
Apr 05, 2021
Sell 15.4 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 319
48.43 USD
3 years ago
Apr 05, 2021
Sell 216 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 4531
47.59 USD
3 years ago
Apr 05, 2021
Sell 12.9 K USD
Rose Geoffrey Beran
Chief Commercial Officer
- 266
48.46 USD
3 years ago
Apr 05, 2021
Sell 227 K USD
Sung Derrick
Chief Financial Officer
- 4780
47.56 USD
3 years ago
Apr 05, 2021
Sell 10.7 K USD
Sung Derrick
Chief Financial Officer
- 220
48.56 USD
3 years ago
Apr 06, 2021
Sell 131 K USD
Sung Derrick
Chief Financial Officer
- 2825
46.49 USD
3 years ago
Apr 06, 2021
Sell 75.3 K USD
Sung Derrick
Chief Financial Officer
- 1575
47.79 USD
3 years ago
Apr 06, 2021
Sell 29 K USD
Sung Derrick
Chief Financial Officer
- 600
48.33 USD
3 years ago
Mar 30, 2021
Sell 55.1 M USD
BOSTON SCIENTIFIC CORP
10 percent owner
- 1350000
40.8 USD
4 years ago
Oct 05, 2020
Bought 300 K USD
Florin Daniel P
Director
+ 15789
19 USD
4 years ago
Oct 05, 2020
Bought 250 K USD
FERRARI RICHARD M
Director
+ 13157
19 USD
4 years ago
Oct 05, 2020
Bought 500 K USD
Melenikiotou Georgia
Director
+ 26315
19 USD
4 years ago
Oct 05, 2020
Bought 500 K USD
Mead Dana G Jr.
Director
+ 26315
19 USD
7. News
Pulmonx to Present at the Stifel 2024 Healthcare Conference REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET. globenewswire.com - 1 week ago
Wall Street Analysts Predict an 89.61% Upside in Pulmonx (LUNG): Here's What You Should Know The average of price targets set by Wall Street analysts indicates a potential upside of 89.6% in Pulmonx (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 1 week ago
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago. zacks.com - 2 weeks ago
Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024 REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, October 30, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. globenewswire.com - 1 month ago
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024 CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- globenewswire.com - 2 months ago
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024 DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif. , Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at the 2024 World Conference on Lung Cancer (WCLC) in San Diego. prnewswire.com - 2 months ago
Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024. globenewswire.com - 2 months ago
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET. globenewswire.com - 2 months ago
Pulmonx Corporation (LUNG) Q2 2024 Earnings Call Transcript Pulmonx Corporation (NASDAQ:LUNG ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler John Young - Canaccord Frank Takkinen - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Pulmonx Second Quarter 2024 Earnings Conference Call. seekingalpha.com - 3 months ago
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago. zacks.com - 3 months ago
Pulmonx Reports Second Quarter 2024 Financial Results REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024. globenewswire.com - 3 months ago
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston. Management is scheduled to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET. globenewswire.com - 3 months ago
8. Profile Summary

Pulmonx Corporation LUNG

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 250 M
Dividend Yield 0.00%
Description Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Contact 700 Chesapeake Drive, Redwood City, CA, 94063 https://pulmonx.com
IPO Date Oct. 1, 2020
Employees 279
Officers Mr. Steven S. Williamson Chief Executive Officer, President & Director Mr. Mehul Joshi Chief Financial Officer Mr. John B. McKune Vice President & Corporate Controller Mr. Geoffrey Beran Rose Chief Commercial Officer Mr. Sri Radhakrishnan Chief Technical Officer Ms. Marcee M. Maroney Vice President of Marketing Sarah Huber Vice President of Sales (U.S.) Ms. Lisa Paul Chief People Officer Mr. Jérôme Erath Senior Vice President & GM of Europe Middle-East & Africa